Pakistan – Pakistan’s DRAP Creates Guidelines on Conducting Clinical Trials

The Drug Regulatory Authority of Pakistan (DRAP) has published guidelines on the conduct of clinical trials. DRAP’s guideline covers many topics specific to the conduct of studies in Pakistan, such as explanations of the roles of different organizations and how to apply to run clinical trials.

In the guidelines, DRAP provides definitions of clinical trial terms, which follow harmonized global standards, and they cover topics specific to Pakistan. DRAP wants sponsors or principal investigators to send requests to run clinical trials to its Division of Pharmacy Services and will take 60 to 90 days to review applications…